Objective: This review investigates the effectiveness of two cinnamon species, Cinnamomum verum and C. cassia, in diabetes management; their impact on related health conditions and relevant parameters in healthy individuals and safety issues. Methods: PubMed, Cochrane Library, and ScienceDirect were searched from 2000 up to April 2018 for clinical trials using either C. verum or C. cassia in controlling blood glucose and other diabetes-related parameters and conditions.
suggests that people with diabetes are at an increased risk for cognitive decline, vascular dementia, and Alzheimer's disease (Gudala et al., 2013; Ninomiya, 2014; Ojo and Brooke, 2015) , indicating the importance of diabetes management in the ageing population.
Due to the increasing prevalence and chronic nature, T2DM is a global health issue of significant economic importance. According to American Diabetes Association (ADA), the direct medical cost in 2012 was $176 billion in the United States, and average medical expenditure on a diabetes patient was about $13,700 per year: approximately 2.3 times higher than the estimate in the absence of diabetes (ADA, 2013) . In Europe, a study comprising 8 countries (Belgium, France, Germany, Italy, the Netherlands, Spain, Sweden and the United Kingdom) revealed the cost of T2DM to be € 29 billion a year (1999 values) and the estimated average yearly cost € 2834 per patient (Jönsson B and Board., 2002) . In Germany alone, average annual direct cost of medical care was € 5,262, approximately 1.9 times higher compared with costs of age-and sex-matched non-diabetic control subjects (Köster et al., 2006) . Although some of the top-selling medications such as metformin are modestly priced and drug costs for managing T2DM are relatively low (7% of the total healthcare costs for T2DM) (Jönsson B and Board., 2002) , the exploration of blood glucose management using traditional herbal medicines is warranted as it could help prevent the development of T2DM and comorbidities, thereby reducing the direct and indirect costs. Current anti-diabetic drugs such as sulfonylureas and -glucosidase inhibitors help manage blood glucose levels.
However, due to potential side effects such as nausea, dyspepsia and weight gain (Sola et al., 2015; van de Laar, 2008) , it is important to find effective and safer alternatives.
The medicinal properties of cinnamon have been acknowledged since antiquity (De Vos, 2010) . The genus Cinnamomum (Lauraceae) includes more than 250 species, among which Cinnamomum verum J.Presl (synonym: C. zeylanicum Blume, Ceylon cinnamon or true cinnamon) and C. cassia (L.) J.Presl (synonym: C. aromaticum Nees, cassia cinnamon or Chinese cinnamon) are most commonly used as medicines (Nabavi et al., 2015) . The inner bark is used as a circulatory stimulant, a digestive aid, diaphoretic, and antitussive (Bone and J o u r n a l P r e -p r o o f Mills, 2013; Klein and Rister, 1993) . Historically, C. cassia is among the top 14 'simples' (plants that can be used on their own for medicinal purposes, rather than as part of a formula) listed in 12 important texts including Hippocratic Corpus (5 th -4 th century BC), De Materia Medica by Dioscorides (1 st century AD), The Canon of Medicine (volume 2) by Avicenna (980 -1037 AD), and Farmacopea Espanola (1865), while C. verum is one of the top 26 simples, listed in 11 out of the 12 texts (De Vos, 2010) . In The Canon of Medicine, Cinnamomum spp. was among 18 plants that protect the liver from injuries or diseases, and recent studies confirmed the hepatoprotective effect of Cinnamomum spp. using animal models (Shamsi-Baghbanan et al., 2014) . In a 15th-century French herbal 'Le Livre des Simples Medecines', cinnamon was among the six medicinal spices (pepper, ginger, cinnamon, cloves, nutmeg, and mace) . The text states that cinnamon is used 'for weakness of the stomach and liver and to help digestion weakened by cold', 'to restore appetite', 'for recently cracked lips and other sores', and 'for heart ailments and syncope' (Nam, 2014) . In fact, the use of cinnamon to treat digestive tract ailments has continued throughout history (De Vos, 2010) . The European Medicine Agency (EMA) endorses the traditional use of C. verum for symptomatic treatment of mild, spasmodic gastro-intestinal complaints (EMA, 2011b) . At present, cinnamon is on the market as a prophylactic supplement for metabolic syndrome, insulin resistance, T2DM, hyperlipidaemia, and arthritis (Medagama, 2015; Rafehi et al., 2012) .
The major constituents of cinnamon include cinnamaldehyde, cinnamyl acetate, eugenol, catechin, epicatechin, and proanthocyanidins Chen et al., 2014; Kaul et al., 2003; Vallverdú-Queralt et al., 2014) . A number of potential mechanisms for cinnamon have been suggested (Rafehi et al., 2012) , including activation of phosphorylation of insulin receptors -subunits; increased expression of GLUT 4, increase in GLUT 1 mediated glucose uptake, increase in GLP-1, increase in PPAR, inhibition of intestinal glucosidase and pancreatic -amylase, inhibition of gluconeogenesis, and delay of gastric emptying. Preclinical studies demonstrated hypoglycaemic and hypolipidaemic properties of J o u r n a l P r e -p r o o f cinnamon extract and the active constituents (Medagama, 2015) . In vivo studies found improved insulin sensitivity and lowered intestinal carbohydrate absorption after the treatment with cinnamon extract in T2DM model mice (Kim et al., 2006) , a reduction of plasma glucose levels by cinnamaldehyde via insulin secretion from pancreatic -cells (Subash Babu et al., 2007) , insulin-like activity of cinnamon polyphenols (trimers and tetramers of catechin and epicatechin) (Anderson et al., 2004) , blood glucose-lowering effects of polyphenol-enriched C. verum extract (IM et al., 2014b) and polyphenol-enriched decoumarinated C. cassia extract (IM et al., 2014a) , and lowered triglyceride and total cholesterol levels after treatment with cinnamon extract in T2DM model mice (Kim et al., 2006) . PPAR- and  activation in adipocytes (Sheng et al., 2008) and up-regulation of antiinflammatory factors such as tristetraprolin and glucose transporter (GLUT1) in macrophages were also suggested in vitro (Cao et al., 2008) . Using C. verum, Kadan et al. demonstrated a significant gain in GLUT4 on the cell surface of muscle cells, suggesting that C. verum could facilitate glucose uptake into skeletal muscle (Kadan et al., 2013) . Considering that glycemic fluctuations and hyperglycemia trigger endothelial dysfunction and inflammation (Mannucci et al., 2013) , controlling hyperglycemia is likely to reduce the risk of atherogenesis and cardiovascular events. In addition, hyperglycemia and abnormal insulin levels are related to an increased risk of Alzheimer's disease as well as vascular dementia (Gudala et al., 2013; Matsuzaki et al., 2010; Rönnemaa et al., 2008; Young et al., 2006) . Therefore, the hypoglycaemic property of cinnamon may protect against diabetes-related comorbidities such as cardiovascular diseases and dementia.
The EMA states that cinnamon bark contains up to 4% of essential oil consisting primarily of cinnamaldehyde (60-75%) (EMA, 2011a). Herbal preparations equivalent to 2-4g cinnamon per day, or 50-200mg of essential oil, are indicated for symptomatic treatment of mild spasmodic gastrointestinal complaints including bloating and flatulence (EMA, 2011b).
C. cassia has traditional use similar to C. verum, however the two species have differences in their constituents as summarised elsewhere (Ranasinghe et al., 2013) : C. verum bark oil J o u r n a l P r e -p r o o f contains 49.9-62.8% trans-cinnamaldehyde while C. cassia contains almost 95% cinnamaldehyde. In addition, it is notable that C. cassia contains coumarin up to 1% (Krieger et al., 2013) , whereas C. verum contains coumarin only at trace or undetectable levels (Krieger et al., 2013; Ranasinghe et al., 2013) . Considering that ohydroxyphenylacetaldehyde (o-HPA), a metabolite of coumarin, is hepatotoxic, long-term consumption of C. cassia may pose a health risk (Abraham et al., 2010; Ranasinghe et al., 2013) , while C. verum would likely be free of this particular risk (Medagama, 2015) .
Therefore it has been suggested that C. verum should be used in preference to C. cassia in treating T2DM (Medagama, 2015) .
Five reviews have examined the efficacy of cinnamon species for diabetes (Table 1) .
A systematic review and meta-analysis conducted in 2012 (Leach and Kumar, 2012) assessed ten RCTs published between 2003 and 2010. The authors concluded that there is insufficient evidence to support the use of cinnamon as an anti-diabetes mellitus treatment. On the other hand, systematic review and meta-analysis by Akilen et al. (2012) found a significant decrease in HbA1c and fasting blood glucose levels (Akilen et al., 2012) . A year later, In 2013, a meta-analysis (Allen et al., 2013) found significant improvement in fasting blood glucose levels as well as in lipid parameters, although no significant effect was found on HbA1c levels. Another meta-analysis (Alanazi and Khan, 2015) reflected the findings of Allen et al. (2013) . Medagama (2015) found improved glycaemic control in T2DM patients without other medications as well as those with pre-diabetes and high pre-treatment HbA1c.
Medagama concluded that cinnamon is potentially useful as an adjuvant therapy in managing T2DM. The difference in conclusions between those reviews is interesting, ranging from insufficient evidence to a useful add on treatment. Of note, none of these reviews separately assessed the different cinnamon species. Overall this suggests the evidence for effective intervention in T2DM is growing, but provisional, given the heterogeneity of cinnamon species, preparations, and dosages.
The herbal CONSORT statement (Gagnier et al., 2006) considers it "imperative that reports of RCTs provide clear and complete descriptions of the herbal intervention", J o u r n a l P r e -p r o o f including the Latin binomial name together with botanical authority and family name in addition to common names for each herbal ingredient. If the species is unspecified it is difficult to establish causality. Given the potential confusion, substitution or adulteration of herbal products, (Fong, 2002; Posadzki et al., 2012) , this review focuses on interventions using two named cinnamon species: C. cassia and C. verum.
While Medagama discussed the safety issue of high coumarin content in C cassia, suggesting C. verum syn zeylanicum as a safer alternative, none of the five reviews evaluated the differential efficacy of the two main medicinal cinnamon species and their dosages as a T2DM intervention and whether the coumarin content of these species is a cause for concern. Furthermore, these reviews did not assess the differential evidence for the suitability of the two cinnamon species for related clinical conditions, nor the effect of the two cinnamon species on blood sugar related parameters in healthy populations. Hence, this study seeks to review the current evidence for C. cassia and C. verum in the treatment of T2DM and metabolically related conditions, their effects on blood sugar related parameters in healthy populations, and their safety profile.
Methods

Database searching for clinical evidence
The current review focuses on trials investigating the effects of C. verum and C. cassia on the levels of blood glucose and other relevant parameters in diabetes management. To consider prophylactic benefits and effectiveness in the management of diabetes, trials on T2DM patients, as well as subjects with other related clinical conditions and healthy individuals, were reviewed.
Search strategy
To find clinical evidence for the anti-diabetic effects of C. verum and C. cassia, searches were conducted using databases, namely PubMed/Medline, Cochrane Library, and ScienceDirect. Publications not meeting the above criteria, as well as studies using unspecified or different cinnamon species, or combination products, were excluded. Each author assessed the final selection of studies independently, before final agreement on inclusion.
Coumarin content and safety issues
To assess coumarin contents and potential toxicity of cinnamon species, database searches were conducted for journal articles using the combination of 2 keywords, namely coumarin and either C. verum or C. cassia. PubMed searches were conducted using the following search terms: (1) (Cinnamomum zeylanicum) AND coumarin, (2) 
Results and Discussions
There are 3 most common ways to detect diabetic and prediabetic conditions: fasting blood glucose, HbA1c levels, and glucose tolerance (ADA, 2010; Patel and Macerollo, 2010) .
HbA1c test is a blood test that provides the average blood glucose over the past 3 months.
Oral Glucose Tolerance Test (OGTT) measures glucose tolerance by measuring blood glucose after fasting and after glucose intake. Trials reviewed in this study assessed the effectiveness of cinnamon in T2DM patients using these and related parameters, as well as the effect of C. cassia and C. verum on related conditions and healthy populations.
Cinnamon for diabetes management
A total of 12 database searches (4 for each database: PubMed, ScienceDirect, and Cochrane Library) were conducted using the 4 search terms, and 308 results were obtained. There were 67 results (39 from PubMed, 21 from ScienceDirect, and 7 from Cochrane Library) for 'Cinnamomum verum, 121 results (38 from PubMed, 37 from ScienceDirect, and 46 from Cochrane Library) for 'Cinnamomum zeylanicum', 100 results (10 from PubMed, 78 from ScienceDirect, and 12 from Cochrane Library) for 'Cinnamomum cassia', and 20 results (7 from PubMed, 6 from ScienceDirect, and 7 from Cochrane Library) for 'Cinnamomum aromaticum'. After removing duplicates and screening from title and abstract, 32 articles remained. Seven studies were removed, three due to the lack of information on the cinnamon species used in the trials (Altschuler et al., 2007; Khan et al., 2010; Mirfeizi et al., 2016) ; three using a different species: C.burmanii as the formulation CinSulin (Anderson et al., 2016; Roussel et al., 2009; Ziegenfuss et al., 2006) ; one using a combination product including zinc gluconate (Wainstein et al., 2011) . The remaining 25 studies of 997 participants were selected for reviewing (Table 1) . The selection process is presented in a flowchart (Figure 1) .
Fifteen studies were conducted on T2DM patients, among which twelve trials used C.
cassia (Akilen et al., 2010; Blevins et al., 2007; Crawford, 2009; Gullapalli et al., 2013;  J o u r n a l P r e -p r o o f Hasanzade et al., 2013; Khan et al., 2003; Lu et al., 2012; Mang et al., 2006; Sengsuk et al., 2016; Soni and Bhatnagar, 2009; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006) (n=730) and three trials used C. verum (Azimi et al., 2014; Azimi et al., 2016; Vafa et al., 2012 ) (n=123). Dosages were 1-3g per day, and durations of the trials ranged from 30 days to four months. Reduction in fasting blood glucose or other diabetes-related parameters were demonstrated in ten studies (C. cassia 1.5-6g per day for 40 days -four months, or C. verum 3g per day for 8 weeks) (Akilen et al., 2010; Azimi et al., 2014; Azimi et al., 2016; Crawford, 2009; Gullapalli et al., 2013; Khan et al., 2003; Lu et al., 2012; Mang et al., 2006; Sengsuk et al., 2016; Soni and Bhatnagar, 2009) , and a study showed postprandial blood glucose decrease after 40-day administration of C. cassia (2g per day) (Soni and Bhatnagar, 2009 ).
On the other hand, four studies found no significant effect on fasting blood glucose levels after 1-1.5g C. cassia administration for 30 daysthree months (Blevins et al., 2007; and one study looked at postprandial glucose and insulin levels after 14-day administration of C. cassia (Solomon and Blannin, 2009) . Positive outcomes were obtained in the trials using C. cassia (3-5g) (Hlebowicz et al., 2009; Mettler et al., 2009; Blannin, 2007, 2009) , and 1g alcoholic extract of C. verum (Beejmohun et al., 2014) .
However, C. verum 3g had no effect on postprandial glucose and lipid levels after a high fat meal (Markey et al., 2011) .
3.1.1 T2DM: C. cassia and C. verum compared ( Out of 15 studies on T2DM patients, 12 used C. cassia and three used C. verum. Of these 15 studies, ten reported significant improvements with a variety of outcome measures including HbA1c, fasting blood glucose, postprandial blood glucose and insulin as well as the pathometabolically related parameters of blood pressure. Eight of these ten positive outcomes were from the 12 C. cassia studies (Akilen et al., 2010; Blevins et al., 2007; Crawford, 2009; Gullapalli et al., 2013; Hasanzade et al., 2013; Khan et al., 2003; Lu et al., 2012; Mang et al., 2006; Sengsuk et al., 2016; Soni and Bhatnagar, 2009; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006) and the remaining positive outcomes were two of the three C. verum studies (Azimi et al., 2014; Vafa et al., 2012) . Furthermore, C. cassia 1.5-6g per day, aqueous extract 120-360 mg per day for 40 daysthree months, or C. verum 3g per day for eight weeks reduced triglyceride and LDL levels in T2DM patients (Khan et al., 2003; Lu et al., 2012; Sengsuk et al., 2016) . Considering that body fat is a significant diabetes-associated risk factor for cardiovascular disease (Howard et al., 2000) , C. cassia and C. verum may help prevent the development of vascular comorbidity in T2DM. Five studies (Azimi et al., 2016; Blevins et al., 2007; Hasanzade et al., 2013; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006) reported no improvements in the analysed outcome measures including fasting glucose levels and HbA1c. Four of these were C. cassia studies (Blevins et al., 2007; Hasanzade et al., 2013; Suppapitiporn et al., 2006; Vanschoonbeek et al., 2006) and one was a C. verum study (Azimi et al., 2016) . The dosages for three of C. cassia studies were 1g per day (Blevins et al., 2007; Hasanzade et al., 2013) , and 1.5g per day (Suppapitiporn et al., 2006;  J o u r n a l P r e -p r o o f Vanschoonbeek et al., 2006) . These dosages are low compared to the most commonly used dosage of 3g per day. In addition, the duration in the Hasanzade study was 30 days (Hasanzade et al., 2013) , which is likely too short to meaningfully assess changes in HbA1c levels, an outcome measure used in the study. Administration of 3g per day for eight weeks showed no improvement in a study (Azimi et al., 2016) , which measured blood pressure and endothelial function in T2DM rather than direct blood glucose parameters. This is relevant considering the relationship between poor blood glucose control and hypertension via the development of atherosclerosis may take longer to modify than eight weeks that was provided in the trial. Interestingly, when the same authors reported fasting blood glucose as the outcome measure on this study, a decrease was found (Azimi et al., 2014) , suggesting it is easier to modify this parameter with C. verum than its downstream effects. Both publications (Azimi et al., 2014; Azimi et al., 2016) refer to different datasets within the same study of four individual herbal interventions, including C. verum 3g/day.
Related Clinical Conditions: C. cassia and C. verum compared (Table 2-2)
Four studies were conducted on subjects with clinical conditions other than T2DM:
IGT (Wickenberg et al., 2012; Wickenberg et al., 2014) as a pre-diabetic condition, and obesity (Gutierrez et al., 2016; Magistrelli and Chezem, 2012) , which is a risk factor for diabetes. In obese subjects, ingestion of C. cassia 5g and 6g suppressed postprandial glucose rise (Gutierrez et al., 2016; Magistrelli and Chezem, 2012) .. In a study with IGT participants, Wickenberg et al. found no impact of C. cassia 12g per day for 12 weeks on the fasting glucose and insulin levels (Wickenberg et al., 2014) . These findings suggest the potential effectiveness of C. cassia at 5g-6g per day, but not as high as 12g per day for the prevention of T2DM development in individuals with high risk.
Turning to C. verum, Wickenberg also authored a study on C. verum, and found no effect of C. verum 6g on postprandial blood glucose and insulin levels (Wickenberg et al., 2012) . (Table 2-3) A study on healthy subjects found that postprandial insulin rise was suppressed by 3g C. cassia but not by 1g (Hlebowicz et al., 2009 ), suggesting that the critical dosage of C. cassia lies between 1 and 3 g per day. Single administration of C. cassia (3g or 5g) (Hlebowicz et al., 2009; Solomon and Blannin, 2007) and C. cassia (3g) for 14 days (Solomon and Blannin, 2009 ) led to decrease in postprandial glucose response. Mettler et al. reported that C. cassia 4g had a significant impact on postprandial glucose levels only when taken in combination with acetic acid (Mettler et al., 2009) . Interestingly, in the historical text 'Le Livre des Simples Medecines', combination of cinnamon with vinegar is suggested for its effectiveness (Nam, 2014) . These data suggest that C. cassia powder 3g or C. cassia taken with vinegar, could help control blood glucose levels and associated parameters, which may be of benefit to T2DM patients.
In two C. verum studies in healthy populations, ingestion of an alcoholic extract (1g) of C. verum led to a reduction in postprandial glucose and insulin levels (Beejmohun et al., 2014) , while ingestion of a dose of C. verum 3g with a high fat meal (Markey et al., 2011) did not influence postprandial changes in glucose and triacylglycerol levels.
Overall, C. cassia (≥ 3g) in healthy individuals had positive outcomes in postprandial glucose control, while evidence supporting C. verum is insufficient.
Safety issues
Adverse events in the clinical trials
Ten studies positively reported no adverse events. Fourteen studies did not report whether or not any adverse events occurred during the studies. One study reported a subject developing a rash (Crawford, 2009 ). Another study (Wickenberg et al., 2014) , using 12g/day C .cassia for 12 weeks, whilst not actively reporting adverse events, did measure liver enzymes, and found no change in serum transaminases. (Table 3) J o u r n a l P r e -p r o o f Due to the high coumarin content of C. cassia, C. verum has been suggested to be a safe alternative intervention for diabetes (Medagama, 2015) . Coumarin (2H-chromen-2-one) is a naturally occurring constituent of many plants, and long term use of cinnamon as a flavouring agent is generally considered safe (Leach and Kumar, 2012) . It was first isolated from tonga beans Dipteryx odorata (Aubl.) Willd. in 1820 and chemically synthesized coumarin had been marketed as a food flavouring agent for a long time until its hepatotoxic potential was discovered in laboratory animals in the middle of the 20 th century. From the 1970s, coumarin was approved as a medicine to treat oedemas as well as tumours in several countries.
Coumarin and safety
However some patients developed severe hepatotoxicity, which led to the withdrawal of products from the market in 1990s (Abraham et al., 2010) . Coumarin is metabolized via two major pathways: detoxification by 7-hydroxylation and the formation of 3,4-epoxide intermediate, the latter of which leads to the generation of a hepatotoxic metabolite o-HPA.
As the 7-hydroxyation pathway is predominant in primates including humans, humans are less susceptible to coumarin hepatotoxicity compared to rodents. However, clinical data revealed that a human population subgroup reacts sensitively to coumarin (Loprinzi et al., 1999; Schmeck-Lindenau et al., 2003) , although the underlying mechanism is unknown (Abraham et al., 2010) .
To evaluate the coumarin-related safety issues of the two cinnamon species, database searches were conducted. The search retrieved a total of 19 results (18 results for PubMed, 1 for ScienceDirect), of which five articles are selected and summarised in Table 3 . Abraham et al. (2011) compared the absorption of coumarin after oral administration of isolated coumarin and C. cassia in different preparations (capsules, tea, and rice pudding) (Abraham et al., 2011) . They found that coumarin in isolation and in C. cassia were equally absorbed, and that C. cassia tea exhibited the fastest and highest coumarin absorption, compared to capsules and rice pudding. Data on the coumarin contents in different cinnamon species confirmed higher coumarin levels in C. cassia compared to C. verum (Table 3) . Three independent studies conducted on the coumarin levels of C. cassia reported considerably different values: 2.57±0.08g/kg (2.512-2.628 g/kg) (Krieger et al., 2013) , 0.201±0.104 g/kg (0.085-0.310g/kg) J o u r n a l P r e -p r o o f (Wang et al., 2013) , and 1.60±1.70g/kg (0.33-6.5 g/kg) (Lv et al., 2010) , which could be due to several factors including extraction methods, analytical methods, and the sources of plant materials. In fact, those studies were conducted using different extraction and analytical methods, namely 80% methanol extraction without heat or sonication and LC-MS and DIP-APCI-MS analyses (Krieger et al., 2013) , methanol extraction with sonication and UPLC-UV/MS (Wang et al., 2013) , and pressurized liquid extraction with ethyl acetate at 160°C and and GC-MS (Lv et al., 2010) , which could underlie the variability in these studies.
Furthermore, plant materials were obtained from different sources, such as German retail market (Krieger et al., 2013) , commercial source in China and the United States (Wang et al., 2013) , and different regions of China (Lv et al., 2010) . As demonstrated by Lv et al., coumarin contents of C. cassia could considerably vary (from 0.33 to 6.50 mg/g) depending on the geographical origins (Lv et al., 2010) , which is likely due to different climatic conditions, plant age, and harvest timings. In addition, coumarin levels could vary depending on which plant parts were used. A study compared the levels of coumarin and other constituents in the bark, shaved bark (without cork layer), and twig of C. cassia, both used in traditional East Asian medicines, and found that coumarin in cinnamon twig was less than one-third compared to cinnamon bark, and shaved cinmmamon bark contained the highest levels of coumarin (Chen et al., 2016) . Importantly, a study showed that a de-coumarinated polyphenol-enriched C. cassia extract, prepared using a novel procedure, was effective in lowering blood glucose levels in T2DM rats (IM et al., 2014a) , indicating that the selection of extraction procedure could significantly enhance the safety of C. cassia. Of note, C. burmannii (Nees & T. Nees) Blume, commonly also known as 'cassia' cinnamon (Avula et al., 2015) , has characteristically high coumarin levels, which is distinct from C. cassia (Avula et al., 2015; Chen et al., 2014; Wang et al., 2013) , and C. burmannii was likely referred to as 'cassia' cinnamon in some reports. Importantly, Wang et al. reported that C. cassia contains higher levels of cinnamaldehyde: C. cassia (18.5±2.9 g/kg, n=4) > C. verum (11.2±5.5 g/kg, n=17) (Wang et al., 2013) . Considering that anti-diabetic actions of cinnamon is at least partly mediated by cinnamaldehyde , the dosage of C. verum should be carefully J o u r n a l P r e -p r o o f considered as a replacement for C. cassia. In fact, short-term administration ( 14days) of C. verum (3g and 6g) were ineffective (Markey et al., 2011; Wickenberg et al., 2012) , while C. cassia 3 -6 g were effective (Hlebowicz et al., 2009; Magistrelli and Chezem, 2012; Mettler et al., 2009; Solomon and Blannin, 2007) , suggesting that C. cassia has higher potency compared to C. verum. Overall, it is important to identify botanical origin, geographical origin, plant parts, and extraction procedures, in using and reporting analytical as well as clinical trial data.
In addition to liver damage caused by coumarin, allergic reactions should be considered as a possible adverse effect, as several cases of contact dermatitis have been reported (Ackermann et al., 2009; Calapai et al., 2014; Isaac-Renton et al., 2015) . In fact, a subject developed a rash after consuming C. cassia 1g per day in a trial (Crawford, 2009) , however this was the only adverse reaction reported in any of the trials considered in this review. In fact, no case reports of interactions were identified therefore it was considered unlikely that it would affect the effectiveness of conventional drugs (Edwards et al., 2015) .
However, pharmacovigilance is important for any potential interactions and additive effects.
Both C. verum and C. cassia, in therapeutic doses, should be avoided during pregnancy (Edwards et al., 2015; Gardner and McGuffin, 2013) .
Limitation of the study
Due to the scarcity of available data, this study included both randomised placebo-controlled and open-label trials. In addition, compared to C. cassia, only a few trials have been conducted with C. verum. This is limiting as the discussion is based on evidence supported by a small number of studies with less vigorous study designs. More robust studies are needed in the future.
Concluding remarks
J o u r n a l P r e -p r o o f
Most clinical studies were conducted using C. cassia, which was originally used as an antidiabetic medicine and listed as the unique origin of 'Cortex cinnamomi' in the Chinese pharmacopoeia (Lv et al., 2010) . Evidence suggests that oral administration of C. cassia 3-6g per day could improve glucose metabolism in T2DM patients and healthy individuals, while effectiveness was inconsistent below 1.5g. However, heterogeneity in the methods used in the trials as well as quality issues including lack of botanical authentication compromise the evidence for the efficacy and safety.
Therapeutic potency depends on the levels of active constituents. Considering that medicinal plants in general contain a number of bioactive compounds, the levels of which could be affected by many factors such as geographical origin, plant parts, and crude drug processing, it is important to assess the chemical properties of botanical medicines before using and evaluating the therapeutic potency and safety. In addition, due to the high coumarin content of C. cassia, future trials should be designed taking into account the assessment of potential hepatotoxicity by including liver function tests over suitable trial durations. These efforts would allow a more reliable safety and efficacy evaluation of C. cassia. as a diabetes intervention.
On the other hand, data are scarce and inconclusive for the effectiveness of C. verum.
It should be noted that the interchangeability of the two cinnamon species as a diabetes intervention is not established and there is currently no standardisation method for quality control. It is important for practitioners to consider possible differences in the potency between the two species as well as within the same species, and potential risk associated with coumarin consumption. Given the low coumarin content of C. verum there is an opportunity for more robust RCTs, of longer duration and larger participant numbers giving greater power, to investigate whether this species has potential for this growing patient group. The effective and safe dosage practices for different species should be built on scientific data through careful examination and comparison, as well as drawing on long-standing traditional usages. Key to this is clarity about the intervention including establishing botanical authenticity. Such work could not only benefit T2DM patients and those diagnosed as pre-J o u r n a l P r e -p r o o f diabetic, but also the growing number of diseases that are related to insulin resistance, and hence favourably ameliorate the personal, social and economic costs of these conditions.
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